Myriad Genetics Inc. (MYGN)

MYGN trades at $8.24, 17.7% above the near-term max pain of $7 expiring Oct 17, 2025 (11 days). Expect downward pressure as dealers benefit from price declining toward max pain. Max pain is rising across expirations ($1-$7), reflecting growing call interest at higher strikes. Key magnetic zone at 4 where 2 expirations converge. High dispersion in max pain levels suggests competing forces and potential volatility.

Max pain for MYGN shows an upward trend from 1 to 7, suggesting bullish positioning in longer-dated options. The 143% spread signals divergent expectations across timeframes. Most levels below 8.24 may cap rallies. Weekly expirations influence price 2-3 days before expiry; monthlies throughout their final week.